Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.

@article{Zinman2013EfficacyAS,
  title={Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.},
  author={Bernard Zinman and J. Hans DeVries and Bruce W Bode and David Russell-Jones and Lawrence A Leiter and Alan Charles Moses and Thue Johansen and Robert E. Ratner},
  journal={The lancet. Diabetes & endocrinology},
  year={2013},
  volume={1 2},
  pages={123-31}
}
BACKGROUND Results of an exploratory phase 2 study showed that insulin degludec, a basal insulin with an action profile of longer than 42 h, provided similar glycaemic control when injected three times a week (IDeg 3TW) to once-daily insulin glargine (IGlar OD). To provide further evidence, we did two phase 3 trials to compare the efficacy and safety of IDeg 3TW with IGlar OD in insulin-naive patients with type 2 diabetes. METHODS In two 26 week, randomised, open-label, parallel group, non… CONTINUE READING